AU2022333823A1 - Preparation for oral administration containing triazine derivative - Google Patents
Preparation for oral administration containing triazine derivative Download PDFInfo
- Publication number
- AU2022333823A1 AU2022333823A1 AU2022333823A AU2022333823A AU2022333823A1 AU 2022333823 A1 AU2022333823 A1 AU 2022333823A1 AU 2022333823 A AU2022333823 A AU 2022333823A AU 2022333823 A AU2022333823 A AU 2022333823A AU 2022333823 A1 AU2022333823 A1 AU 2022333823A1
- Authority
- AU
- Australia
- Prior art keywords
- formula
- vii
- compound represented
- compound
- measurement
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
Applications Claiming Priority (19)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021-189932 | 2021-11-24 | ||
| JP2021189932 | 2021-11-24 | ||
| JP2021-191635 | 2021-11-26 | ||
| JP2021191635 | 2021-11-26 | ||
| JP2022-006725 | 2022-01-19 | ||
| JP2022006725 | 2022-01-19 | ||
| JP2022012386 | 2022-01-28 | ||
| JP2022-012386 | 2022-01-28 | ||
| JP2022017132 | 2022-02-07 | ||
| JP2022-017132 | 2022-02-07 | ||
| JP2022027629 | 2022-02-25 | ||
| JP2022-027629 | 2022-02-25 | ||
| JP2022046304 | 2022-03-23 | ||
| JP2022-046304 | 2022-03-23 | ||
| JP2022142767 | 2022-09-08 | ||
| JP2022-142767 | 2022-09-08 | ||
| CN202211151791.9A CN116514734A (zh) | 2021-11-24 | 2022-09-21 | 三嗪衍生物的制造方法和含有三嗪衍生物的口服给与的制剂 |
| CN202211151791.9 | 2022-09-21 | ||
| PCT/JP2022/043092 WO2023027198A1 (ja) | 2021-11-24 | 2022-11-22 | トリアジン誘導体を含有する経口投与する製剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2022333823A1 true AU2022333823A1 (en) | 2024-05-02 |
Family
ID=85321709
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2022333823A Pending AU2022333823A1 (en) | 2021-11-24 | 2022-11-22 | Preparation for oral administration containing triazine derivative |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240148741A1 (https=) |
| EP (1) | EP4289432A4 (https=) |
| JP (2) | JP7253866B1 (https=) |
| KR (1) | KR20230119022A (https=) |
| AU (1) | AU2022333823A1 (https=) |
| WO (1) | WO2023027198A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL300412A (en) | 2020-08-24 | 2023-04-01 | Gilead Sciences Inc | Phospholipid compounds and their uses |
| TW202344257A (zh) | 2020-10-16 | 2023-11-16 | 美商基利科學股份有限公司 | 磷脂化合物及其用途 |
| LT4122926T (lt) | 2021-04-14 | 2025-07-25 | Shionogi & Co., Ltd. | Triazino dariniai, turintys virusų replikaciją slopinantį poveikį, ir juos apimanti farmacinė kompozicija |
| EP4289432A4 (en) * | 2021-11-24 | 2025-01-15 | Shionogi & Co., Ltd | PREPARATION FOR ORAL ADMINISTRATION CONTAINING TRIAZINE DERIVATIVES |
| WO2023054732A2 (ja) * | 2022-01-19 | 2023-04-06 | 塩野義製薬株式会社 | 新型コロナウイルス感染症治療用医薬 |
| US11655240B1 (en) * | 2022-05-10 | 2023-05-23 | Beijing Grand Johamu Pharmaceutical Company, Ltd. | Crystal form of compound and fumaric acid, pharmaceutical composition and method for treating coronavirus-induced diseases |
| WO2023193818A1 (zh) * | 2022-04-08 | 2023-10-12 | 湖北九康通生物医药有限公司 | 一种多取代三嗪烷类化合物的合成方法 |
| WO2024031089A1 (en) | 2022-08-05 | 2024-02-08 | Gilead Sciences, Inc. | Sars-cov2 main protease inhibitors |
| CN116554106A (zh) * | 2023-04-28 | 2023-08-08 | 扬州市普林斯医药科技有限公司 | 一种6-氯-2-甲基-2h-吲唑-5-胺的制备方法 |
| CN116589410B (zh) * | 2023-05-29 | 2024-05-03 | 济南国鼎医药科技有限公司 | 一种6-氯-2-甲基-2h-吲唑-5-胺的合成方法 |
| CN116621817B (zh) * | 2023-07-20 | 2023-09-29 | 爱斯特（成都）生物制药股份有限公司 | 一种富马酸恩赛特韦的晶型及其制备方法、药物组合物和用途 |
| CN117357531A (zh) * | 2023-09-08 | 2024-01-09 | 湖北九康通生物医药有限公司 | 一种药物组合物、其制备方法和其应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999036410A1 (en) * | 1998-01-13 | 1999-07-22 | Scriptgen Pharmaceuticals, Inc. | Triazine antiviral compounds |
| PL2399910T3 (pl) * | 2009-02-13 | 2014-09-30 | Shionogi & Co | Pochodne triazyny jako antagoniści receptora p2x3 i/albo p2x2/3 i kompozycja farmaceutyczna zawierająca je |
| WO2012009258A2 (en) | 2010-07-13 | 2012-01-19 | Edward Roberts | Peptidomimetic galanin receptor modulators |
| CN103153968B (zh) | 2010-08-10 | 2016-02-03 | 盐野义制药株式会社 | 三唑衍生物及含有其的具有镇痛作用的药物组合物 |
| TW201331188A (zh) | 2011-12-15 | 2013-08-01 | Shionogi & Co | 經取代之三□衍生物及含有其之醫藥組成物 |
| TWI637949B (zh) | 2013-06-14 | 2018-10-11 | 塩野義製藥股份有限公司 | 胺基三衍生物及含有其等之醫藥組合物 |
| WO2019087884A1 (ja) * | 2017-10-31 | 2019-05-09 | 富士フイルム株式会社 | 組成物、抗菌組成物、抗ウイルス用組成物、抗ノロウイルス用組成物、スプレー、ワイパー |
| PH12021552872A1 (en) | 2020-04-05 | 2022-03-21 | Pfizer | Compounds and methods for the treatment of covid-19 |
| US11351149B2 (en) | 2020-09-03 | 2022-06-07 | Pfizer Inc. | Nitrile-containing antiviral compounds |
| EP4282420A4 (en) * | 2021-01-20 | 2024-11-27 | National University Corporation Hokkaido University | ANTIVIRAL AGENT |
| EP4313097A4 (en) * | 2021-03-29 | 2025-03-19 | Shireen Nature Company for General Trading, Ltd. | Willow extract and its use in treating coronavirus infection, inflammation, and associated medical conditions |
| LT4122926T (lt) * | 2021-04-14 | 2025-07-25 | Shionogi & Co., Ltd. | Triazino dariniai, turintys virusų replikaciją slopinantį poveikį, ir juos apimanti farmacinė kompozicija |
| CN113801097B (zh) | 2021-09-27 | 2022-11-22 | 成都施贝康生物医药科技有限公司 | 二氢嘧啶类化合物、其制备方法及用途 |
| CN113666914B (zh) | 2021-09-27 | 2022-06-07 | 成都施贝康生物医药科技有限公司 | 二氢嘧啶类化合物及其制备方法和用途 |
| CN113773300B (zh) | 2021-09-27 | 2022-10-11 | 成都施贝康生物医药科技有限公司 | 磺酰胺类化合物、其制备方法及用途 |
| CN113735838B (zh) | 2021-09-27 | 2022-07-08 | 成都施贝康生物医药科技有限公司 | 二氢嘧啶类化合物、其制备方法及用途 |
| CN113620888B (zh) | 2021-09-27 | 2023-06-06 | 成都施贝康生物医药科技有限公司 | 二氢嘧啶类化合物及其制备方法和应用 |
| EP4289432A4 (en) | 2021-11-24 | 2025-01-15 | Shionogi & Co., Ltd | PREPARATION FOR ORAL ADMINISTRATION CONTAINING TRIAZINE DERIVATIVES |
-
2022
- 2022-11-22 EP EP22861484.8A patent/EP4289432A4/en active Pending
- 2022-11-22 WO PCT/JP2022/043092 patent/WO2023027198A1/ja not_active Ceased
- 2022-11-22 US US18/277,445 patent/US20240148741A1/en active Pending
- 2022-11-22 JP JP2022574839A patent/JP7253866B1/ja active Active
- 2022-11-22 KR KR1020237025438A patent/KR20230119022A/ko active Pending
- 2022-11-22 AU AU2022333823A patent/AU2022333823A1/en active Pending
-
2023
- 2023-03-24 JP JP2023048827A patent/JP7466731B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230119022A (ko) | 2023-08-14 |
| JP7253866B1 (ja) | 2023-04-07 |
| WO2023027198A1 (ja) | 2023-03-02 |
| JP7466731B2 (ja) | 2024-04-12 |
| US20240148741A1 (en) | 2024-05-09 |
| EP4289432A4 (en) | 2025-01-15 |
| EP4289432A1 (en) | 2023-12-13 |
| JPWO2023027198A1 (https=) | 2023-03-02 |
| JP2023078413A (ja) | 2023-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240148741A1 (en) | Formulation for oral administration, comprising triazine derivative | |
| TWI815396B (zh) | 具有病毒增殖抑制作用之三嗪衍生物及含有其等之醫藥組合物 | |
| CN116514734A (zh) | 三嗪衍生物的制造方法和含有三嗪衍生物的口服给与的制剂 | |
| TW202320793A (zh) | 含有三嗪衍生物之醫藥組合物 | |
| AU2017214589A1 (en) | Sulfonamide derivative and pharmaceutical composition containing same | |
| US20250127788A1 (en) | Pharmaceutical composition containing triazine derivative | |
| US20250025459A1 (en) | Covid-19 treatment medicine characterized by combining 3cl protease inhibitor and covid-19 treatment drug | |
| AU2023202177A1 (en) | Pharmaceutical for treating novel coronavirus infection | |
| JP2024178473A (ja) | ウイルス増殖阻害活性を有する二環性含窒素複素環誘導体およびそれらを含有する医薬組成物 | |
| CN108929329B (zh) | 2-氮杂环-5-三氟甲基-8-硝基苯并(硫代)吡喃-4-酮类化合物 | |
| JP7261529B1 (ja) | ウイルス増殖阻害作用を有するトリアジン誘導体の製造方法 | |
| CN116782904A (zh) | 含有三嗪衍生物的医药组合物 | |
| HK40114521A (en) | Pharmaceutical composition containing triazine derivative | |
| TWI916636B (zh) | 新型冠狀病毒感染症治療用醫藥 | |
| AU2024307335A1 (en) | Pharmaceutical composition containing uracil derivative | |
| BR122023002208A2 (pt) | Composições farmacêuticas compreendendo derivados de triazina tendo efeito inibidor de propagação de vírus, inibidores e usos | |
| WO2025217212A1 (en) | Mac1 inhibitors and uses thereof | |
| BR122023002208B1 (pt) | Composições farmacêuticas compreendendo derivados de triazina para o tratamento e/ou prevenção de covid-19 | |
| AU2024309726A1 (en) | Preparation containing uracil derivative | |
| BR112022023272B1 (pt) | Derivados de triazina tendo efeito inibidor de propagação de vírus e cocristal do mesmo com ácido fumárico | |
| HK40098963A (zh) | 治疗癌症的方法 |